| Website | neurovista.com |
| Category | BioTech |
| Phone | 206-267-3700 |
| Employees |
| TOTAL | $50.3M |
| FUNDING TOTAL | $50.3M |
| Series B, 5/07 Advanced Technology Ventures Delphi Ventures Three Arch Partners Sprout Group Foundation Medical Partners | $33.8M |
| Venture Round, 8/10 Advanced Technology Ventures Delphi Ventures Foundation Medical Partners GBS Ventures | $16.5M |
NeuroVista Corporation is a medical device company pioneering new technologies for the management and treatment of epilepsy, a condition that affects roughly 3 million people in the United States. The defining characteristic of epilepsy is recurrent seizures that strike without warning. Symptoms may range from brief suspension of awareness, to loss of consciousness, to violent convulsions. Unlike other neurological conditions, such as stroke or Alzheimer’s disease which tend to develop later in life, epilepsy often affects people in the prime of their lives, with the majority between 15 and 64 years of age.
